Further, and as demonstrated here, the immune infiltrate of CMS4 tumors comprises both tumor-reactive and immune-suppressive cells, resulting in a strong rationale for blocking the TGF-β pathway in tumors that exhibit features of TGF-β activation in their microenvironment to unleash pre-existing T cell reactivity. This evidence concerns the gene TGFB1 and neoplasm.